The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary
BOX 1-1
Speaker’s Perspectives on Barriers to the Collection ofClinical Validity and Utility Data for Genomic Diagnostic Tests
Various stakeholders require different types and levels of evidence (e.g., doctors, patients, FDA, payers, evidence-based review groups)
Limited or nonexistent funding for randomized controlled trials of genomic tests
Length of time needed for clinical trials to be completed
High cost of archiving specimens from therapeutic clinical trials
Lack of access to annotated clinical specimens
nisms to obtain it so that the promise of the human genome project and genomic diagnostic testing can be fully realized.
The report that follows summarizes the presentations and discussions by the expert panelists. Chapter 2 provides the different stakeholder perspectives on the type and level of evidence needed for decision making. Approaches for evidence generation are discussed in Chapter 3. Chapters 4 and 5 examine ways to overcome the barriers to evidence generation and strategies for moving forward. Final remarks are provided in Chapter 6, and the workshop agenda, biographical sketches of the panelists, and list of attendees are included in the appendixes.
